Catalyst Event
Novo Nordisk A/S (NVO) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
3/19/2026, 12:00:00 AM
On March 19, 2026, the U.S. FDA is scheduled to approve Wegovy HD (semaglutide 7.2 mg) for adults with obesity or overweight, with a high price impact (≥10%) expected as this blockbuster approval significantly increases market potential.
Korean Translation
2026년 3월 19일, 미국 FDA는 비만 또는 과체중 성인을 위한 위고비 HD(세마글루타이드 7.2mg)를 승인할 예정이며, 블록버스터 약물 승인은 시장 잠재력을 크게 확대하므로 10% 이상의 높은 주가 영향이 예상됨.
Related Recent Events
Lululemon Athletica Inc (LULU) · Earnings Release
Q1 2026 earnings release scheduled. This is an estimated date based on past reporting schedules.
5/28/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled; a price impact of at least 1% is expected.
4/30/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Q1 2026 earnings release with adjusted EPS guidance of $1.12 to $1.18, for which a ≥1% price impact is estimated, scheduled.
4/15/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Other
Quarterly dividend ex-date of $0.63 per share on 2026-04-15, for which a ≥1% price impact is estimated, scheduled.
4/15/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
New target action date for the FDA's decision on oral obesity drug orforglipron, following an extension of the review period announced on January 15, 2026, scheduled; a price impact of at least 1% is expected.
4/10/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
Quarterly dividend of $1.25 per share, a 3% increase, will have its ex-dividend date on March 27, 2026. The dividend is payable on April 10, 2026. A 1% price impact is estimated due to the dividend increase, scheduled.
3/27/2026, 12:00:00 AM